Advaxis Sinks On Delayed Disclosure Of Clinical Hold

Advaxis Inc. fell 25.8% in after-hours trading on Oct. 6 when the company said the US FDA placed a clinical hold on its investigational new drug (IND) application for axalimogene filolisbac (ADXS-HPV) – a disclosure that was made five days after Advaxis received word from the agency.